Supplementary Figure 4 from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Year: 2023
Type: supplementary-materials
Abstract: PDF - 1338KB, A, Annexin V apoptotic assay was performed in parental HeLa cells treated with and without tiplaxtinin (30 and 50 microM) and exposed to the apoptotic inducing agent, mitomycin C at 5 microg/ml. The anti-apoptotic effects of PAI-1 overexpression were abrogated in all cells treated with tiplaxtinin. B, Annexin V apoptotic assay was performed in HeLa clones (HeLa-PAI-1OE and HeLaEmpty) after exposing the cells to the apoptotic inducing agent, mitomycin C at 5 ?g/ml. Overexpression of PAI-1 in HeLa clones elicited protection against mitomycin C induced cell death (HeLa-PAI-1KD-12 and HeLa-PAI-1KD-18). C, Western blot analysis was performed on the above cell lines confirming the induction of the key apoptotic proteins cleaved caspase-3, cleaved-PARP as well as Fas and FasL. Staining for β-actin served as a control. At least three independent experiments consisting of each condition tested in triplicate wells was used to calculate mean + SD values. *, p < 0.05. D, In a cell adhesion assay, treatment of HeLa cells with tiplaxtinin resulted in a dose-dependent reduction in the ability of the cells to adhere to substrate. E, In an anoikis assay, treatment of HeLa cells with tiplaxtinin for 24 hrs resulted in significant induction of anoikis.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362609193